Patents by Inventor Dolores Garcia Gravalos
Dolores Garcia Gravalos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20020099066Abstract: 1 Compounds having formula (I) wherein R3, R4, R7, and R8 are independently selected from the group consisting of hydrogen, lower alkyl, halogen, amine, mono(lower)alkylamine, di(lower)alkylamine, phenyl, or substituted phenyl possess antitumor activity and are new with the exception of the compound in which R3, R4, R7, R8 are all hydrogen and the compound in which R3 and R7 are hydrogen, R4 chlorine, and R8 is a 2-nitrophenyl group.Type: ApplicationFiled: July 11, 2001Publication date: July 25, 2002Inventors: Carmen Avendano, Jose Maria Perez, Maria del Mar Blanco, Jose Carlos Menendez, Dolores Garcia Gravalos, Jesus Angel de la Fuente, Maria Jesus Martin
-
Publication number: 20020062023Abstract: Palau'amine, of formula I below, may be isolated from a sponge (:). The compound may be used in the manufacture of pharmaceutical compositions for the treatment of tumors, fungal infections and immunosuppressive affections.Type: ApplicationFiled: August 10, 2001Publication date: May 23, 2002Applicant: PharmaMar, s.a.Inventors: Robin Bryan Kinnel, Henning-Peter Gehrken, Paul Josef Scheuer, Dolores Garcia Gravalos, Glynn Thomas Faircloth
-
Patent number: 6391900Abstract: The present invention discloses new cytotoxic tris(oxazole)-containing macrolides having the formula: wherein X represents a lower alkyl; R1 and R2 represent hydrogen or lower alkyl; R3a represents hydrogen, and R3b represents or R3a and R3b together represent oxygen; R4 represents hydrogen, lower alkoxy or lower alkyl; R5 represents hydrogen, carbamoyl, or lower alkanoyl; R6a represents hydrogen, and R6b represents hydroxy, or R6a and R6b together represent oxygen; R7 represents hydrogen, lower alkyl, or hydroxymethyl; R8 represents lower alkoxy or lower alkyl; Y1 represents hydrogen or methyl, and y2 represents hydrogen, or Y1 and Y2 together represent a double bond. Also disclose are methods for treating mammals using the macrolides and pharmaceutical preparations including the macrolides.Type: GrantFiled: January 12, 2001Date of Patent: May 21, 2002Assignee: Instituto Biomar S.A.Inventors: Tatsuo Higa, Dolores Garcia Gravalos, Jose Luis Fernandez Puentes
-
Patent number: 6350743Abstract: Shermilamine D, a novel cytotoxic pyridoacridine alkaloid of Formula 1, has been isolated from the tunicate Cystodytes violatinctus. The structure of the compound has been established on the basis of 1-D and 2-D NMR data.Type: GrantFiled: February 22, 2001Date of Patent: February 26, 2002Assignee: Instituto Biomar, S.A.Inventors: Yoel Kashman, Ganit Koren-Goldshlager, Maurice Aknin, Dolores Garcia Gravalos
-
Patent number: 6214793Abstract: The present invention is directed to a novel depsipeptide has been isolated from a new marine strain L-13-ACM2-092 belonging to the family Micromonosporaceae. Its production by aerobic fermentation under controlled conditions of the strain, and the isolation and purification of PM-93135 are described herein. The compound and the fermentation broth demonstrate significant activity against several cancer cell lines. The compound also shows activity against several gram positive bacteria.Type: GrantFiled: September 24, 1997Date of Patent: April 10, 2001Assignee: Pharma Mar, s.a.Inventors: Julia Perez Baz, Francisco Romero Millan, Teresa Garcia De Quesada, Dolores Garcia Gravalos
-
Patent number: 6087370Abstract: The lamellarin compounds disclosed herein have been found to be inhibitors of MDR, i.e., acquired multidrug resistance, which has become a major problem in the treatment of various cancers. The lamellarin compounds disclosed herein have also been found to be cytotoxic to MDR cells. MDR is believed to be associated with certain alterations in tumor cells, including an over-expression of a certain high molecular weight membrane glycoprotein and a decrease in the ability of the tumor cell to accumulate and retain chemotherapeutic agents. The present invention is thus directed to methods of treating MDR-type tumors with an effective anti-MDR amount (either inhibitory or cytotoxic) of one or more lamellarin compounds, which compounds have been found to be effective antitumoral agents against MDR cells.Type: GrantFiled: December 18, 1998Date of Patent: July 11, 2000Assignee: Pharma Mar, s.a.Inventors: Jose Luis Fernandez Puentes, Dolores Garcia Gravalos, Ana Rodriguez Quesada
-
Patent number: 6025466Abstract: A new cyclic heptapeptide, trunkamide A, with antitumor activity has been isolated from a Lissoclinium sp. collected on the Great Barrier Reef, Australia.Type: GrantFiled: February 19, 1999Date of Patent: February 15, 2000Assignee: Pharma Mar, s.a.Inventors: Bruce Frederick Bowden, Dolores Garcia Gravalos
-
Patent number: 5925671Abstract: Antitumor isocoumarins are of general formula (III) where R is --CONH.sub.2 or --CH(CH.sub.3).sub.2, or a pharmaceutically acceptable addition salt thereof. The compound wherein R is --CONH.sub.2 is the known compound amicoumacin A. The compound wherein is --CH(CH.sub.3).sub.2 is a new compound which can be obtained from fermentation of the new marine bacterium Bacillus sp. strain M-00-PHD-090, CECT 4546.Type: GrantFiled: November 6, 1997Date of Patent: July 20, 1999Assignee: Pharma Mar, s.a.Inventors: Librada Canedo Hernandez, Cristina Acebal Sarabia, Dolores Garcia Gravalos
-
Patent number: 5852033Abstract: The lamellarin compounds disclosed herein have been found to be inhibitors of MDR, i.e., acquired multidrug resistance, which has become a major problem in the treatment of various cancers. The lamellarin compounds disclosed herein have also been found to be cytotoxic to MDR cells. MDR is believed to be associated with certain alterations in tumor cells, including an over-expression of a certain high molecular weight membrane glycoprotein and a decrease in the ability of the tumor cell to accumulate and retain chemotherapeutic agents. The present invention is thus directed to methods of treating MDR-type tumors with an effective anti-MDR amount (either inhibitory or cytotoxic) of one or more lamellarin compounds, which compounds have been found to be effective antitumoral agents against MDR cells.Type: GrantFiled: June 29, 1995Date of Patent: December 22, 1998Assignee: Pharma Mar, s.a.Inventors: Jose Luis Fernandez Puentes, Dolores Garcia Gravalos, Ana Rodriguez Quesada
-
Patent number: 5849540Abstract: The present invention is directed to a novel depsipeptide has been isolated from a new marine strain L-13-ACM2-092 belonging to the family Micromonosporaceae. Its production by aerobic fermentation under controlled conditions of the strain, and the isolation and purification of PM-93135 are described herein. The compound and the fermentation broth demonstrate significant activity against several cancer cell lines. The compound also shows activity against several gram positive bacteria.Type: GrantFiled: September 24, 1997Date of Patent: December 15, 1998Assignee: Pharma Mar, S.A.Inventors: Julia Perez Baz, Francisco Romero Millan, Teresa Garcia De Quesada, Dolores Garcia Gravalos
-
Patent number: 5786377Abstract: The pyrrolo?3,2-e! derivatives of the present invention have the formulae (I), (Ia) and (II) wherein R is substituted or unsubstituted aryl or heteroaryl, R' is substituted or unsubstituted alkanoyl, alkenoyl, alkynoyl, arenocarbonyl or heteroarenocarbonyl and X is chloro, bromo, iodo or alkylsulfonyl or arylsulfonyl. The compounds find utility as agents having antitumor activity, and are thus useful agents in the treatment of cancer.Type: GrantFiled: January 29, 1997Date of Patent: July 28, 1998Assignee: Universidad de Santiago de CompostelaInventors: Jose Delamano Garcia, Gabriel Tojo Suarez, Carmen Lopez Goti, Jesus Fernandez Almeida, Dolores Garcia Gravalos, Glynn Thomas Faircloth
-
Patent number: 5744623Abstract: Terpene-quinone with antitumor activity defined from a cyclocondensation reaction of Diels-Alder, used to obtain families or series of said compounds having a new structure and presenting a cytotoxic activity to cellular cultures P-388, A-549, HT-29 and MEL-28, with levels of IC.sub.50 lower than 1 microgram per unit of milliliter.Type: GrantFiled: October 4, 1996Date of Patent: April 28, 1998Assignee: Pharma Mar, s.a.Inventors: M.sup.a Dolores Garcia Gravalos, Marina Gordaliza Escobar, Santana Jose M.sup.a Miguel Del Corral, Ma del Mar Mahiques Bujanda, Arturo San Feliciano Martin
-
Patent number: 5716963Abstract: Said derivatives have the general formula (I) and are: ##STR1## (I-A) 4,6,7-trimethyl-5,8,8a,10a-tetrahydro-1H-1-azaanthracen-2,9,10-trione; (I-B) 2-ethoxy-3-methyl-1-azaanthracen-9,10-dione; (I-C) 3-ethyl-1,8-dihydro-1H-1,8-diazaanthracen-2,7,9,10-tetraone; (I-d) 2-acethoxy-3-methyl-1,8-diazaanthracen-2,9,10-trione; (I-e) 6-fluor-4-methyl-1H-1,8-diazaanthracen-2,9,10-trione; (I-f) 6-dimethylamino-4-methyl-1H-1,8-diazaanthracen-2,9,10-trione; (I-g) 4-methyl-5-(2-nitrophenyl)-5,8-dihydro-1H-1,8-diazaanthracen-2,9,10-trione ; (I-h) 3,5-dimethyl-1,8-dihydro-1,8-diazaanthracen-2,7,9,10-tetraone; (I-i) 3,6-difluor-1,8-diazaanthracen-9,10-dione; (I-j) 6-methyl-3-phenyl-1H-1,8-diazaanthracen-2,9,10-trione; (I-k) 3-fluor-4-methyl-1-dihydro-1-azaanthracen-9,10-dione; 3-fluor-1-azaanthracen-1,10-dione. Application as antitumor agents.Type: GrantFiled: March 27, 1996Date of Patent: February 10, 1998Assignee: Universidad Complutense De MadridInventors: Carmen Avendano Lopez, Dolores Garcia Gravalos
-
Patent number: 5681813Abstract: The present invention is directed to a novel depsipeptide has been isolated from a new marine strain L-13-ACM2-092 belonging to the family Micromonosporaceae. Its production by aerobic fermentation under controlled conditions of the strain, and the isolation and purification of PM-93135 are described herein. The compound and the fermentation broth demonstrate significant activity against several cancer cell lines. The compound also shows activity against several gram positive bacteria.Type: GrantFiled: April 6, 1994Date of Patent: October 28, 1997Assignee: Pharma Mar, s.a.Inventors: Julia Perez Baz, Francisco Romero Millan, Teresa Garcia De Quesada, Dolores Garcia Gravalos
-
Patent number: 5631384Abstract: The compounds (I) are useful as intermediates in the synthesis of hexahydroareno(e)cyclopropa(c)indol-4-ones with antitumoral activity.Type: GrantFiled: July 3, 1996Date of Patent: May 20, 1997Assignee: Pharma-Mar, S.A.-PharmarInventors: Koen Alexander, Jose Delamano Garcia, Benedikt Sas, Gabriel Tojo Suarez, Dolores Garcia Gravalos
-
Patent number: 5605905Abstract: Azaanthracene-triones of the formula: ##STR1## (in which: R.sup.1, R.sup.2, R.sup.4 and R.sup.5 are the same or are different and each is a hydrogen atom or a lower alkyl group;R.sup.3 is a hydrogen atom, a lower alkyl group, a phenyl group or an amino-substituted phenyl group; andX is a --CH--, .dbd.N-- or --NH--, whereby the ring containing the group X is a benzene, pyridine or dihydropyridene ring)have antitumoral activity.Type: GrantFiled: March 28, 1995Date of Patent: February 25, 1997Assignee: Universidad Complutense de MadridInventors: Carmen Avendano, Miguel A. Alonso, Modesta Espada, Dolores Garcia-Gravalos, Jose C. Mendendez, Blanca Ocana, Jose M. Perez
-
Patent number: 5571927Abstract: The areno[e]indols have the formula (I). The methods comprises: (a) reacting (VI) with an aldehyde Ar"--CHO to obtain (VII); (b) oxidizing (VII) to yield the cetone (VIII); (c) reating (VIII) with a strong base and thereafter with an acycle chloride ClCOR, to produce (IX); (d) subjecting to a photochemical cyclization (IX) to produce (I). In said formulas Ar is phenyl or substituted phenyl; Ar' is radical (i) or (ii); R is an acyle group, Ar" is a phenyl, pyrolyl, furanyl or thiophenyl group substituted up to three times by any of the radials R, R.sup.1, R.sup.2, or R.sup.3. The compounds (I) are useful as intermediates in the synthesis of hexahydroareno(e)cyclopropa(c)indol-4-ones with antitumoral activity.Type: GrantFiled: May 19, 1994Date of Patent: November 5, 1996Assignee: Pharma-Mar, S.A.- PharmarInventors: Koen Alexander, Jose Delamano Garcia, Benedikt Sas, Gabriel Tojo Suarez, Dolores Garcia Gravalos